Biosyntia is securing future in-licensing rights to natural isoflavonoids made from a revolutionizing new, bio-based process, thereby expanding their development pipeline of nutraceutical ingredients with a wide array of possible uses through a collaboration with French biotech start-up Lantana.
Biosyntia was among 40 scale-ups selected from all over the world to take part in the Sustainable Industry Challenge on January 7 and 8.
Co-founder of Biosyntia, Hans Genee has been awarded with a position on the list 'Innovators Under 35 Europe 2019'. Selected by the jury from more than 1,000 candidates!
The top CEO’s, founders and investors in the synthetic biology industry gathered for the SynBioBeta European Thought Leader Retreat. The retreat took place in the Austrian Alps in Aug 2019. Besides hiking, they attended workshops designed to collectively understanding the trends, roadblocks and outlook for the industry over the next 10 years.
Biosyntia attended Vitafoods Europe in Geneva in May 2019, a great platform for generating new business and building profitable relationships. The global nutraceutical supply chain comes together; covering four key sectors; ingredients and raw materials, finished products, private label and services, equipment & machinery.
Biosyntia has today announced a Series A investment inthe company of 4 million euros from Sofinnova Partners, a new investor, andNovo Seeds, an existing investor.
The entrepreneurs, Gene and Lausten tells about howthey formed Biosyntia together with Morten Sommer, while they were allfinishing their deegres. They hope to encourage ...
Together with seven other finalist, Biosyntia was selected to pitch atthe event, in front of a panel of experts. The expert panel received manyapplications from entrepreneuers and innovators from around the world, but onlyinvited ...
In September 2016,Biosyntia was recognized by EuropaBio as one of the Most Innovative BiotechSMEs in Europe within biotechnology. The initiative recognizes highlyinnovative small and medium sized enterprises in Europe that ...
In the collaborationBiosyntia will use its multiplex engineering tools for the simultaneousmodification of several
targets identified as bottlenecks in the vitaminpathway ...
September 2016. Gen9,Inc., a pioneer in the development of scalable technologies for synthesizingand assembling DNA, announced the winners of its fourth annual G-Prize contest.Biosyntia was ...
In spring 2016, theEuropean Commission awarded 6.3 million Euros to a four-year collaborativeproject on data-driven design of cells and microbial communities forapplications ranging from human
Together withresearchers from the Center for Biosustainability at the Technical Universityof Denmark, Biosyntia developed a synthetic selection system for ...
In September 2016, Hans Genee and Andreas Laustsen were selected among Europes 10 most inspiring innovators under 30. Thanks to Labiotech.eu!
In May 2015 BiosyntiaApS completed a DKK 12.5 M financing round with Novo Seeds as lead investor.“We invest worldwide and only in the companies with unique differentiators andcompetitive edge ...
February 2015. We are proud to be among the 25 mostpromising cleantech start-ups in the Nordic awarded by the Nordic CleantechOpen.
In October 2014, Biosyntia was recognized by EuropeBioas one of the Top 5 Most Innovative SMEs in Europe within biotechnology.EuropaBio is a trade association with the mission to create an innovative anddynamic biotechnology industry in Europe by communicating the benefits ofbiotech to all corners of society.
In November 2013, Biosyntia was awarded Best LifeScience Company Presentation at the Nordic Venture Forum in Copenhagen,Denmark. The Nordic Venture Forum promotes the innovative, attractive, andrewarding investment environment of the Nordic and Baltic countries.
In December 2013, Biosyntia as a partner in the PROMYSconsortium received substantial funding through the EU’s FP7 programme. Theconsortium focuses on synthetic pathway construction, cell factoryoptimization, and control of populations during fermentation.
In November 2014, Biosyntia was again awarded BestCompany Presentation at the Nordic Venture Forum in Copenhagen,Denmark. The Nordic Venture Forum promotes the innovative, attractive, andrewarding investment environment of the Nordic and Baltic countries.
In June 2013, Biosyntia received a Pre-Seed Grant fromNovo A/S. Novo A/S is a private company fully owned by the Novo NordiskFoundation and responsible for managing the Foundation’s assets. As holdingcompany for the Novo Group, Novo A/S is the major shareholder in the publiclylisted companies Novo Nordisk A/S and Novozymes A/S.
In June 2013, Biosyntia was chosen as one of the 10best startup stories by Europe Unlimited. Through networking entrepreneurs,investors, corporations, researchers, and advisors Europe Unlimited helpsEurope’s dynamic technology innovators become World leaders in their field.
In September 2012, Biosyntia was awarded BestPresentation at the European Food Venture Forum in Aarhus, Denmark. TheEuropean Food Venture Forum offers a unique platform for food high-growthcompanies, technology corporations, and international investors to exchangeknowledge and build lasting business co-operations.
Biosyntia was among the top 5 finalists in the Intel GlobalChallenge. The Intel Global Challenge at UC Berkeley is the largest startup competition globally. Here, the best of more than 140,000 participating engineers and scientists present how they plan to make the World a better place through their innovations and entrepreneurial skills.
In September 2012, Biosyntia was awarded Best EuropeanStartup at the Intel Business Challenge in Sopot, Poland, thereby securing aUSD 25,000 prize. The Intel Business Challenge is the largest startupcompetition in Europe with more than 40,000 participants.
In June 2012, Biosyntia received an ExploratoryPre-Seed Grant of USD 85,000 from Novo. Novo is a private companyfully owned by the Novo Nordisk Foundation and responsible for managing theFoundation’s assets. As holding company for the Novo Group, Novo A/S is themajor shareholder in the publicly listed companies Novo Nordisk A/S andNovozymes A/S.
Biosyntia was awarded Most PromisingGreentech GRØN DYST (GREEN BATTLE) at the Technical University of Denmark, thereby securing USD 10,000. The GRØN DYST Student Conference isa unique opportunity for DTU students to present their projects to fellow students, DTU alumni, as well as invited guests, such asbusiness people and politicians.
In November 2012, Biosyntia was awarded Best Global Idea at Cleantech Open in San José,California, thereby securing a USD 100,000 prize. The Cleantech Open runsthe World’s largest accelerator for cleantech startups. Their mission is tofind, fund, and foster entrepreneurs that address today’s mosturgent energy, environmental, and economic challenges
In June 2012,Biosyntia was awarded Best Cleantech in Denmark at the Venture Cup StartupCompetition in Copenhagen, thereby securing USD 10,000. Venture Cup is oneof Europe’s largest and most trusted non-profits to help make startups happen.